Metabolic dysfunction-associated steatohepatitis

2 trials MedDRA PT
2 Registered trials
0 Recruiting
1 Unique sponsors
1 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Erythropoietin analogue 1 substance
Phase III: 2

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

2 trials
  • Glaxosmithkline Research & Development Limited Commercial
    EFIMOSFERMIN ALFA
    2025-523674-16-00 9 countries n=183
    Pending
  • Glaxosmithkline Research & Development Limited Commercial
    EFIMOSFERMIN ALFA
    2025-523675-39-00 9 countries n=132
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Glaxosmithkline Research & Development Limited Commercial 2 Phase III 0
← All indication landscapes